Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

被引：50

作者：

Scott, R. ^{[1
]}

Best, J. ^{[1
]}

Forder, P. ^{[1
]}

Taskinen, M-R ^{[1
]}

Simes, J. ^{[1
]}

Barter, P. ^{[1
]}

Keech, A. ^{[1
]}

Barter, P. ^{[1
]}

Best, J. ^{[1
]}

Colman, P. ^{[1
]}

d'Emden, M. ^{[1
]}

Davis, T. ^{[1
]}

Drury, P. ^{[1
]}

Ehnholm, C. ^{[1
]}

Glasziou, P. ^{[1
]}

Hunt, D. ^{[1
]}

Keech, A. ^{[1
]}

Kesaniemi, Y. A. ^{[1
]}

Laakso, M. ^{[1
]}

Scott, R. ^{[1
]}

Simes, R. J. ^{[1
]}

Sullivan, D. ^{[1
]}

Taskinen, M-R ^{[1
]}

Whiting, M. ^{[1
]}

Ansquer, J-C ^{[1
]}

Fraitag, B. ^{[1
]}

Anderson, N. ^{[1
]}

Hankey, G. ^{[1
]}

Hunt, D. ^{[1
]}

Lehto, S. ^{[1
]}

Mann, S. ^{[1
]}

Romo, M. ^{[1
]}

Li, L. P. ^{[1
]}

Hennekens, C. ^{[1
]}

MacMahon, S. ^{[1
]}

Pocock, S. ^{[1
]}

Tonkin, A. ^{[1
]}

Wilhelmsen, L. ^{[1
]}

Forder, P. ^{[1
]}

Akauola, H. ^{[1
]}

Alford, F. ^{[1
]}

Barter, P. ^{[1
]}

Beinart, I. ^{[1
]}

Best, J. ^{[1
]}

Bohra, S. ^{[1
]}

Boyages, S. ^{[1
]}

Colman, P. ^{[1
]}

Connor, H. ^{[1
]}

Darnell, D. ^{[1
]}

Davis, T. ^{[1
]}

机构：

[1] Univ Sydney, NHMRC Clin Trials Ctr, FIELD Study, Sydney, NSW 2006, Australia

来源：

CARDIOVASCULAR DIABETOLOGY | 2005年 / 4卷 / 1期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1186/1475-2840-4-13

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. Research design and methods: FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. Results: About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement or treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). Conclusion: The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005.

引用

页数：9

共 30 条

[1] Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) [J].

Ansquer, JC ;

Foucher, C ;

Rattier, S ;

Taskinen, MR ;

Steiner, G .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :485-493

[2] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[3] The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] [J].

Barter, P. ;

Best, J. ;

Colman, P. ;

d'Emden, M. ;

Davis, T. ;

Drury, P. ;

Ehnholm, C. ;

Glasziou, P. ;

Hunt, D. ;

Keech, A. ;

Kesaniemi, Y. A. ;

Laakso, M. ;

Scott, R. ;

Simes, R. J. ;

Sullivan, D. ;

Taskinen, M-R ;

Whiting, M. ;

Ansquer, J-C ;

Fraitag, B. ;

Anderson, N. ;

Hankey, G. ;

Hunt, D. ;

Lehto, S. ;

Mann, S. ;

Romo, M. ;

Li, L. P. ;

Hennekens, C. ;

MacMahon, S. ;

Pocock, S. ;

Tonkin, A. ;

Wilhelmsen, L. ;

Forder, P. ;

Akauola, H. ;

Alford, F. ;

Barter, P. ;

Beinart, I. ;

Best, J. ;

Bohra, S. ;

Boyages, S. ;

Colman, P. ;

Connor, H. ;

Darnell, D. ;

Davis, T. ;

Davoren, P. ;

Lepre, F. ;

De Looze, F. ;

d'Emden, M. ;

Duffield, A. ;

Fassett, R. ;

Flack, J. .

CARDIOVASCULAR DIABETOLOGY, 2004, 3 (1)

[4] The metabolic syndrome: prevalence in worldwide populations [J].

Cameron, AJ ;

Shaw, JE ;

Zimmet, PZ .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2004, 33 (02) :351-+

[5] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].

Colhoun, HM ;

Betteridge, DJ ;

Durrington, PN ;

Hitman, GA ;

Neil, HAW ;

Livingstone, SJ ;

Thomason, MJ ;

Mackness, MI ;

Charlton-Menys, V ;

Fuller, JH .

LANCET, 2004, 364 (9435) :685-696

[6]

Collins R, 2003, LANCET, V361, P2005

[7] Effects of fibrates on serum metabolic parameters [J].

Elisaf, M .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (05) :269-276

[8] Cardiovascular outcomes in type 2 diabetes - A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study [J].

Elkeles, RS ;

Diamond, JR ;

Poulter, C ;

Dhanjil, S ;

Nicolaides, AN ;

Mahmood, S ;

Richmond, W ;

Mather, H ;

Sharp, P ;

Feher, MD .

DIABETES CARE, 1998, 21 (04) :641-648

[9] LDL SUBCLASS PHENOTYPES AND TRIGLYCERIDE-METABOLISM IN NON-INSULIN-DEPENDENT DIABETES [J].

FEINGOLD, KR ;

GRUNFELD, C ;

PANG, MY ;

DOERRLER, W ;

KRAUSS, RM .

ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (12) :1496-1502

[10]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

← 1 2 3 →